1st Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
3rd Department of Pediatrics, Aristotle University School of Health Sciences, Hippokration General Hospital, Thessaloniki, Greece.
Epidemiol Infect. 2021 Feb 24;149:e70. doi: 10.1017/S0950268821000455.
As most children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present with mild symptoms or they are asymptomatic, the optimal strategy for molecular testing it is not well defined. The aim of the study was to determine the extent and aetiology of molecular testing for SARS-CoV-2 in Greek paediatric departments during the first phase of the pandemic and identify possible differences in incidence, depending on the age group and geographical area. We conducted a nationwide study of molecular testing for SARS-CoV-2 of children in paediatric departments between March and June 2020. A total of 65 paediatric departments participated in the study, representing 4901 children who were tested for SARS-CoV-2 and 90 (1.8%) were positive. Most paediatric cases were associated with topical outbreaks. Adolescents 11-16 years had the highest positivity rate (3.6%) followed by children 6-10 years (1.9%). However, since the testing rate significantly differed between age groups, the modified incidence of SARS-CoV-2 infection per age group was highest in infants <1 year (19.25/105 population). Most children tested presented with fever (70.9%), respiratory (50.1%) or gastrointestinal symptoms (28.1%). Significant differences were detected between public and private hospitals regarding the positivity rate (2.34% vs. 0.39%, P-value <0.001). Significant variation in SARS-CoV-2 molecular testing positivity rate and incidence between age groups indicate discrepancies in risk factors among different age groups that shall be considered when ordering molecular testing.
由于大多数感染严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的儿童仅表现出轻度症状或无症状,因此其分子检测的最佳策略尚未明确。本研究旨在确定在大流行的第一阶段希腊儿科部门对 SARS-CoV-2 进行分子检测的程度和病因,并根据年龄组和地理位置确定发病率的差异。我们对 2020 年 3 月至 6 月期间儿科部门儿童的 SARS-CoV-2 进行了全国性的分子检测研究。共有 65 个儿科部门参与了该研究,代表了 4901 名接受 SARS-CoV-2 检测的儿童,其中 90 名(1.8%)呈阳性。大多数儿科病例与局部暴发有关。11-16 岁青少年的阳性率最高(3.6%),其次是 6-10 岁儿童(1.9%)。然而,由于各年龄组的检测率存在显著差异,因此按年龄组修正的 SARS-CoV-2 感染发病率在<1 岁婴儿中最高(19.25/105 人)。大多数接受检测的儿童表现出发热(70.9%)、呼吸道(50.1%)或胃肠道症状(28.1%)。公立和私立医院之间的阳性率存在显著差异(2.34%比 0.39%,P 值<0.001)。不同年龄组之间 SARS-CoV-2 分子检测阳性率和发病率的显著差异表明,不同年龄组之间的危险因素存在差异,在进行分子检测时应考虑这些差异。